Magazine article Drug Topics

FDA Approves Antibiotic for CDAD, Oral Treatment for Hepatitis C Infection

Magazine article Drug Topics

FDA Approves Antibiotic for CDAD, Oral Treatment for Hepatitis C Infection

Article excerpt



(Dificid, Optimer Pharmaceuticals)

On May 27, 201 1, FDA approved fidaxomicin for the treatment of adults with Clostridium diffkile-assoäated diarrhea (CDAD), Fidaxomicin works by inhibiting RNA synthesis via RNA polymerases and acts locally in the gastrointestinal tract to target C. diffidk with minimal systemic absorption.

Efficacy, Hdaxomidn's efficacy was demonstrated in 2 randomized, active-controlled, double-blind trials enrolling a total of 564 adult patients with CDAD, Both trials compared fidaxomicin 200 mg twice daily for 10 days to vancomycin 125 mg 4 times daily for 10 days. Enrolled patients had either no prior history or only 1 episode of CDAD in the previous 3 months and were not suffering from a life-threatening or fulminant infection, At the end of the 10-day treatment course, clinical response was similar between the fidaxomicin and vancomycin groups. Additionally, the sustained clinical response rate (25 days after the end of treatment) showed fidaxomicin to be superior to vancomycin.

Safety. The safety of fidaxomicin was evaluated in the 2 trials mentioned above. The most common adverse reactions noted in these trials were nausea, vomiting, abdominal pain, gastrointestinal hemorrhage, anemia, and neutropenia. Thirty-three patients receiving fidaxomicin withdrew from the study because of an adverse reaction. Vomiting was the most common adverse reaction to result in fidaxomicin (and vancomycin) discontinuation.

Dosing. The recommended dose is one 200-mg tablet taken twice daily with or without food, No dose adjustment for fidaxomicin is required in patients with renal dysfunction. The impact of hepatic dysfunction on the pharmacokinetics of fidaxomicin has not been evaluated, but since the drug and its metabolites do not undergo hepatic metabolism, no dose adjustment is expected.


(lelaprevir, Vertex Pharmaceuticals)

Current standard- of -care treatment for patients with chronic hepatitis C (CHC) is 48 weeks of peginterferon alfa and ribavirin; however, <50% of patients respond to therapy, FDA approved telaprevir in combination with peginterferon alfa and ribavirin for the treatment of genotype 1 CHC in adult patients with compensated liver disease, including cirrhosis, who are treatmentnaive or who have been previously treated with interferon-based treatment, including prior null responders, partial responders, and relapsers, The safety and efficacy of telaprevir have not been established in co-infected HCV/HIV and HCV/HBV patients.

Efficacy. The efficacy of telaprevir was evaluated in three phase 3 clinical trials that randomly assigned approximately 2,250 adult patients who were either previously untreated or who had received previous therapy. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.